Blockchain Registration Transaction Record

Soligenix Advances Novel Light Therapy for Hard-to-Diagnose Skin Cancer

Soligenix develops HyBryte™, a novel visible light therapy for early-stage cutaneous T-cell lymphoma (CTCL). The treatment targets malignant cells while minimizing damage to healthy tissue.

This development matters because CTCL is notoriously difficult to diagnose in its early stages, often leading to delayed treatment and poorer outcomes for patients. Current ultraviolet-based phototherapies carry significant long-term safety risks, including increased cancer risk with cumulative exposure. HyBryte's visible light activation represents a potentially safer, more targeted approach that could transform treatment for this rare but devastating cancer. For the broader rare disease community, Soligenix's progress demonstrates how specialized biopharmaceutical companies can address critical gaps in treatment where larger pharmaceutical firms may not invest. The company's dual focus on both rare diseases and public health threats (through its vaccine programs) shows a comprehensive approach to addressing significant medical challenges that affect vulnerable populations worldwide.